Lupin launches generic Wellbutrin XL Tablets in the US
Lupin Limited has launched the generic Wellbutrin XL tablets in the United States, the company informed the bourses.
Wellbutrin XL is used to treat major depressive disorder in adults and has US sales of $758 mn, till May 2017, as per data available by IMS.
The stock on the NSE was trading at Rs 1,184 per share higher by Rs 3 per share or 0.3%. The stock has delivered negative returns of 19% in a period of one year and has underperformed the BSE Sensex and BSE Healthcare indices over the same time span.
Lupin Limited is the seventh-largest company by market capitalization; and the 10th largest generic pharmaceutical company by revenue, globally. The company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.
Stock view :-
Lupin Ltd is currently trading at Rs 1184, up by Rs 3.3 or 0.28% from its previous closing of Rs 1180.7 on the BSE.
The scrip opened at Rs 1180.7 and has touched a high and low of Rs 1194 and Rs 1173.5 respectively. So far 1035398(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 53332.35 crore.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1750 on 29-Jul-2016 and a 52 week low of Rs 1080 on 29-May-2017. Last one week high and low of the scrip stood at Rs 1192 and Rs 1152.9 respectively.
The promoters holding in the company stood at 46.69 % while Institutions and Non-Institutions held 41.24 % and 12.06 % respectively.
The stock is currently trading below its 200 DMA.
Lupin Ltd :-
Wellbutrin XL is used to treat major depressive disorder in adults and has US sales of $758 mn, till May 2017, as per data available by IMS.
The stock on the NSE was trading at Rs 1,184 per share higher by Rs 3 per share or 0.3%. The stock has delivered negative returns of 19% in a period of one year and has underperformed the BSE Sensex and BSE Healthcare indices over the same time span.
Lupin Limited is the seventh-largest company by market capitalization; and the 10th largest generic pharmaceutical company by revenue, globally. The company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.
Stock view :-
Lupin Ltd is currently trading at Rs 1184, up by Rs 3.3 or 0.28% from its previous closing of Rs 1180.7 on the BSE.
The scrip opened at Rs 1180.7 and has touched a high and low of Rs 1194 and Rs 1173.5 respectively. So far 1035398(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 53332.35 crore.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1750 on 29-Jul-2016 and a 52 week low of Rs 1080 on 29-May-2017. Last one week high and low of the scrip stood at Rs 1192 and Rs 1152.9 respectively.
The promoters holding in the company stood at 46.69 % while Institutions and Non-Institutions held 41.24 % and 12.06 % respectively.
The stock is currently trading below its 200 DMA.
Lupin Ltd :-
BSE 1,185.00 4.30 (0.36%)
Comments
Post a Comment